<DOC>
	<DOC>NCT00794443</DOC>
	<brief_summary>This is a multi-center double-blind parallel-group study in involutional osteoporosis patients to compare the efficacy and safety of monthly oral intermittent formulation ONO-5920/YM529 with its daily formulation.</brief_summary>
	<brief_title>ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients whose bone mineral density is &lt;70% of Young Adult Mean (YAM), or &lt;80% of YAM who have fragile fracture history Patients can walk on his/her own Written informed consent has been obtained from the patient. Sequential osteoporosis patients or patients with other disorders showing low bone mass Patients with the findings that influence measurement of lumbar vertebral bone mineral density by the DXA method Patients who are unable to keep raising or standing for â‰¥30 min Patients with peptic ulcer Patients who have experienced anamnesis or gastrectomy (total extraction)</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>ONO-5920</keyword>
	<keyword>YM529</keyword>
	<keyword>Bone mineral density</keyword>
	<keyword>Minodronic acid</keyword>
</DOC>